Review Article
PPAR and MEK Interactions in Cancer
Table 1
Combination therapy with PPAR ligands.
| Cancer type | PPAR ligand | Combination | Inhibitor type | Reference |
|
| In vitro |
| CML | TZD18 | Imatinib | Abl, other RPTKs | [122] | NSCLC A549 | Rosiglitazone | Gefitinib | EGFR/Her1 | [144] | Breast
MCF7 | Troglitazone | Herceptin | Mab-Her2/ErbB2 | [145] |
| In vivo (human xenografts or
chemically-induced tumors in rodents) |
| NSCLC A549 | Pioglitazone | PX-866
Gefitinib | PI3K-p110
Her1/EGFR | [149] | Breast (by NMU) | Rosiglitazone | Tamoxifen | SERM | [150] | Thyroid ATC | RS5444 | Paclitaxel | Chemotherapeutic | [120] |
| Clinical studies |
| Melanoma
Sarcoma | Pioglitazone | Rofecoxib Trofosfamide | COX2 Chemotherapeutic | [151–153] | Advanced Solid tumors | LY293111 | Irinotecan Gemcitabine | Chemotherapeutic Chemotherapeutic | [154–156] | Glioblastoma Anaplastic Glioma | Pioglitazone | Rofecoxib
Capecitabine Temozolomide | COX2 Chemotherapeutic
Chemotherapeutic | [157] |
|
|